an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.
![AN2 Therapeutics logo](/files/LOGO/1880438-ANTX.png)
Company profile
Ticker
ANTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
820606654
ANTX stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
14 May 24
10-K/A
2023 FY
Annual report (amended)
14 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
Latest ownership filings
4
Joshua M Eizen
12 Jul 24
SC 13G
Octagon Capital Advisors LP
3 Jul 24
4
Robin Shane Readnour
21 Jun 24
4
Gilbert Lynn Marks
21 Jun 24
4
Margaret M FitzPatrick
21 Jun 24
4
Kabeer Aziz
21 Jun 24
4
Joseph S Zakrzewski
21 Jun 24
4
Melvin K Spigelman
21 Jun 24
4
Patricia A. Martin
21 Jun 24
4
Stephanie Wong
21 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.69 mm | 24.69 mm | 24.69 mm | 24.69 mm | 24.69 mm | 24.69 mm |
Cash burn (monthly) | (no burn) | 168.00 k | 6.10 mm | 5.99 mm | 5.86 mm | 4.94 mm |
Cash used (since last report) | n/a | 649.58 k | 23.58 mm | 23.16 mm | 22.67 mm | 19.10 mm |
Cash remaining | n/a | 24.04 mm | 1.11 mm | 1.53 mm | 2.02 mm | 5.59 mm |
Runway (months of cash) | n/a | 143.1 | 0.2 | 0.3 | 0.3 | 1.1 |
Institutional ownership, Q1 2024
26.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 135.29 mm |
Total shares | 7.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Adjuvant Global Health Technology Fund | 2.60 mm | $0.00 |
Biotechnology Value Fund L P | 1.56 mm | $0.00 |
PFE Pfizer | 1.36 mm | $0.00 |
TCG Crossover GP I | 1.29 mm | $10.02 mm |
Brii Biosciences | 1.05 mm | $0.00 |
Private Advisor | 22.50 k | $73.13 mm |
Chicago Partners Investment | 22.00 k | $52.14 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Jul 24 | Joshua M Eizen | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 94,833 |
19 Jun 24 | Wong Stephanie | Stock Option Common Stock | Grant | Acquire A | No | No | 2 | 64,503 | 129.01 k | 64,503 |
19 Jun 24 | Patricia A. Martin | Stock Option Common Stock | Grant | Acquire A | No | No | 2 | 64,503 | 129.01 k | 64,503 |
19 Jun 24 | Melvin K Spigelman | Stock Option Common Stock | Grant | Acquire A | No | No | 2 | 64,503 | 129.01 k | 64,503 |
19 Jun 24 | Zakrzewski Joseph S | Stock Option Common Stock | Grant | Acquire A | No | No | 2 | 64,503 | 129.01 k | 64,503 |